Prostate-specific antigen-based screening may lead to a modest reduction in prostate cancer-specific mortality but has no effect on overall survival, say the authors of a meta-analysis published in The BMJ.
Caroline McCoach (Helen Diller Family Comprehensive Cancer Center, CA, USA) and Howard (Jack) West (Swedish Cancer Institute, WA, USA) discuss the way forward after great progress with tyrosine kinase inhibitors targeting the epidermal growth factor receptor in non-small-cell lung cancer.
Liza Villaruz (Hillman Cancer Center, PA, USA) examines recent KEYNOTE trials investigating pembrolizumab for advanced non-small-cell lung cancer and the questions they raise regarding patient selection and combination therapy.
Persistent disease-associated mutations detected in the bone marrow 30 days after stem cell transplantation are associated with an increased risk for disease progression among patients with myelodysplastic syndrome, research shows.
A US research team has found that end-of-life care among individuals who undergo allogeneic hematopoietic stem cell transplantation can often be medically intense.
Osimertinib treatment is associated with a reduced risk for central nervous system progression relative to erlotinib or gefitinib in patients with epidermal growth factor receptor-mutated, advanced non-small-cell lung cancer and brain metastases, trial results suggest.
Prostate-specific antigen-based screening may lead to a modest reduction in prostate cancer-specific mortality but has no effect on overall survival, say the authors of a meta-analysis published in The BMJ.
This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.
This program was made possible thanks to independent educational sponsorship from Eli Lilly and Company. Produced by Springer Healthcare Independent Medical Education.
